Trial Profile

Multicenter Phase II Study of the Safety and Efficacy of Nilotinib in Patients with Chronic Phase Chronic Myelogenous Leukemia Showing a Major Molecular Response to Imatinib

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nilotinib (Primary)
Indications Chronic myeloid leukaemia
Focus Therapeutic Use
Acronyms NILSw

Most Recent Events

06 Dec 2016 Results (n=38) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
18 Apr 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
06 Feb 2012 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com